Stock Alert: Genprex Shares Up 53% In Premarket

Shares of Genprex Inc. (GNPX) are surging over 53% in pre-market today, after the company announced a Patent and Technology License Agreement with The University of Texas MD Anderson Cancer Center for combination of its TUSC2 gene therapy with immunotherapies.

Under the licensed agreement, Genprex has been granted an exclusive worldwide license to a portfolio of 16 patent applications and related technology for the treatment of cancer using Genprex's lead drug candidate and TUSC2 gene therapy, known as "Oncoprex" or "GEN-001," in combination with immunotherapies.

Genprex was recently awarded U.S. FDA Fast Track designation for use of Oncoprex combined with Tagrisso for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations whose tumors progressed after treatment with Tagrisso alone.

The company is now preparing to file an Investigational New Drug application to initiate a clinical trial of Oncoprex in combination with pembrolizumab, marketed as Keytruda by Merck, in NSCLC.

The stock has been trading in the range of $0.23 - $7.03 for the past one year, and closed Monday's trade at $2.31, up 4 cents or 1.76%. GNPX is currently trading at $3.54, up $1.23 or 53.25% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT